Evoke Wealth’s Guardant Health GH Stock Holding History

Evoke Wealth’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22	Closed	-$2K	–	1201
2021 Q4	$2K	Hold	22	–	–	﹤0.01%	1044
2021 Q3	$2K	Hold	22	–	–	﹤0.01%	1010
2021 Q2	$3K	Hold	22	–	–	﹤0.01%	984
2021 Q1	$3K	Buy	+22	New	+$3.33K	﹤0.01%	951

Other funds holding GH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Evoke Wealth's GH Position: Q1 2022 in Review

Evoke Wealth sold out of Guardant Health (GH) in Q1 2022, closing a stake of 22 shares — an estimated $2K sold.

Evoke Wealth first reported a position in GH in Q1 2021 and held it in 4 quarters. The position peaked at $3K in Q2 2021. 356 funds tracked by Wall St. Rank hold GH as of Q1 2022.

Evoke Wealth reported no remaining Guardant Health position as of Q1 2022 after selling out during the quarter.
Evoke Wealth sold 22 Guardant Health shares in Q1 2022, an estimated $2K.
Evoke Wealth first reported a position in Guardant Health in Q1 2021 and held it in 4 quarters.
Evoke Wealth's Guardant Health position peaked at $3K in Q2 2021.
356 funds tracked by Wall St. Rank held Guardant Health as of Q1 2022.

Based on Evoke Wealth's 13F filing for Q1 2022, filed 10 May 2022.